Targeting of human interferon antagonists
US10072059B2 · kind B2 · utility
13Cited by
4References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 6, 2017 |
| Grant date | Sep 11, 2018 |
| Priority date | — |
| Expiry date | Jul 6, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.